·   Riyadh, Saudi Arabia — 23 Safar 1447 | August 17, 2025, EVA Pharma one of the fastest-growing pharmaceutical companies in the Middle East and Africa, signed a memorandum of understanding with the Riyadh First Health Cluster, aiming to collaborate in training and scientific research, with a particular focus on clinical research. This step reflects the commitment of both parties to advancing the healthcare sector and strengthening research capabilities in Saudi Arabia.

Dr. Amgad Talaat, Regional Director of EVA Pharma in Saudi Arabia, stated that this cooperation is designed to empower healthcare professionals within the Cluster to acquire the necessary research skills, thereby enhancing the Kingdom’s medical research infrastructure.

Dr. Talaat emphasized EVA Pharma’s strong commitment to supporting education and professional development across the Kingdom. “At EVA Pharma, we don’t limit our contribution to industry and research infrastructure—we also strive to create practical learning opportunities for national talent,” he noted. This commitment was recently demonstrated through EVA Pharma’s student training program, which enabled two Saudi pharmacy students to visit the company’s advanced R&D centers in Egypt for hands-on training in the latest pharmaceutical development and manufacturing technologies.

Talaat added: “We believe that investing in people is the cornerstone of building any healthcare system. EVA Pharma is fully committed to leveraging its expertise and resources to support Saudi talent, in full alignment with the ambitions of Saudi Vision 2030.”

--End of Press Release--

 About EVA Pharma for Industry

EVA Pharma for Industry is a subsidiary of EVA Pharma Holding, one of the fastest-growing healthcare companies in the Middle East and Africa while operating in more than 70 countries worldwide. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.

EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.

With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.

Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.

For more information, please visit: https://www.evapharma.com/en-SA or follow us on X, LinkedIn & Instagram